Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
- PMID: 22944725
- PMCID: PMC3696392
- DOI: 10.1016/j.jcf.2012.08.001
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Abstract
Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.
Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.
Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.
Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Figures



Similar articles
-
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD012300. doi: 10.1002/14651858.CD012300.pub2. Cochrane Database Syst Rev. 2019. PMID: 31845758 Free PMC article.
-
The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis.Pediatr Pulmonol. 2007 Oct;42(10):938-44. doi: 10.1002/ppul.20686. Pediatr Pulmonol. 2007. PMID: 17722007
-
Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.JAMA. 2002 Jun 12;287(22):2958-67. doi: 10.1001/jama.287.22.2958. JAMA. 2002. PMID: 12052125
-
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9. Pediatr Pulmonol. 2012. PMID: 21830317 Free PMC article. Clinical Trial.
-
Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.Clin Chest Med. 2007 Jun;28(2):307-18. doi: 10.1016/j.ccm.2007.02.003. Clin Chest Med. 2007. PMID: 17467550 Review.
Cited by
-
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.Cochrane Database Syst Rev. 2022 Aug 1;8(8):CD008319. doi: 10.1002/14651858.CD008319.pub4. Cochrane Database Syst Rev. 2022. PMID: 35914011 Free PMC article.
-
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD012300. doi: 10.1002/14651858.CD012300.pub2. Cochrane Database Syst Rev. 2019. PMID: 31845758 Free PMC article.
-
Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.J Infect Dis. 2016 Feb 15;213(4):640-8. doi: 10.1093/infdis/jiv436. Epub 2015 Sep 2. J Infect Dis. 2016. PMID: 26333940 Free PMC article.
-
BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.J Immunol Res. 2015;2015:947934. doi: 10.1155/2015/947934. Epub 2015 Jul 26. J Immunol Res. 2015. PMID: 26273683 Free PMC article.
-
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database Syst Rev. 2018 Mar 30;3(3):CD001021. doi: 10.1002/14651858.CD001021.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Nov 14;11:CD001021. doi: 10.1002/14651858.CD001021.pub4. PMID: 29607494 Free PMC article. Updated. Review.
References
-
- Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23:330–335. - PubMed
-
- Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26:458–461. - PubMed
-
- Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67–91. - PubMed
-
- Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–366. - PubMed
-
- Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young childrenwith cystic fibrosis. J Infect Dis. 2001;183:444–452. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical